Shingrix Vaccine Against Shingles Now Partially Reimbursed in france
Good news for seniors and people with weakened immune systems in France: The Shingrix vaccine against shingles is now partially covered by health insurance.
The French National Authority for Health (HAS) announced that 65% of the vaccine’s cost will be covered for seniors and immunodeficient individuals, making it more accessible.
Shingles, a painful viral infection that causes blistering rashes, affects approximately 300,000 people annually in France, with most cases occurring in individuals over 60. Anyone who has had chickenpox is susceptible too shingles.
The Shingrix vaccine offers protection against shingles in 8 out of 10 people. the HAS recommends it for seniors aged 65 and older, as well as immunocompromised individuals from the age of 18.
Prior to this change, the two-dose Shingrix vaccine cost around 300 euros, making it a financial barrier for some.
How does teh Shingrix vaccine compare to other shingles vaccines available in France?
Interview with Dr. Marie Claire Roux: The Impact of Shingrix Vaccine Reimbursement in France
Time.news Editor: welcome, Dr. Roux! Thank you for joining us today to discuss the recent declaration by the French National Authority for Health regarding the Shingrix vaccine. Can you give us a brief overview of what this reimbursement means for seniors and immunocompromised individuals in France?
Dr. Marie Claire Roux: Thank you for having me! The decision to partially reimburse the Shingrix vaccine means that 65% of its cost will be covered for seniors aged 65 and older, as well as for immunocompromised individuals aged 18 and up. This is a important progress because it lowers the financial burden associated with the vaccine, which was previously about 300 euros for the two doses.Now, more people can afford this crucial vaccine, which plays a vital role in preventing shingles, a painful condition that affects many, especially seniors.
Time.news Editor: It’s encouraging to hear that financial barriers are being reduced. Could you explain the importance of the shingrix vaccine in terms of public health?
Dr. Marie Claire Roux: Absolutely. Shingles, which is caused by the reactivation of the varicella-zoster virus— the same virus that causes chickenpox—can lead to serious complications, especially in older adults. with around 300,000 cases diagnosed annually in France, the vaccine is a critical preventive measure.Shingrix has proven to protect against shingles in approximately 80% of those vaccinated, significantly reducing not only the incidence of the disease but also the associated healthcare costs and burden on the healthcare system.
Time.news Editor: That’s quite significant. What should seniors and those with weakened immune systems know about the vaccine and the vaccination process?
Dr. Marie Claire Roux: Seniors and immunocompromised individuals should be aware that the Shingrix vaccine requires two doses, typically administered two to six months apart. It’s essential to consult with a healthcare provider to discuss individual health conditions and any potential contraindications. Given the partial reimbursement, I encourage eligible individuals to make use of this prospect to get vaccinated, as it is a proactive step towards safeguarding their health.
Time.news Editor: How do you see this change impacting the overall vaccination rates against shingles in France?
Dr. marie Claire Roux: With the financial barrier significantly reduced, we can anticipate an increase in vaccination rates among seniors and vulnerable populations. Improved access to the Shingrix vaccine will likely result in broader vaccination coverage,leading to a decline in shingles cases and its complications in the long run. Public health campaigns will be pivotal in raising awareness of this initiative as well.
Time.news Editor: Are there any challenges that still need to be addressed regarding shingles vaccination in France?
Dr. Marie Claire Roux: Yes, while the reimbursement is a positive step, challenges remain.These include ensuring that healthcare providers are adequately educated about the importance of the vaccine so they can advocate effectively to their patients.additionally, public awareness campaigns are crucial to inform the population about the availability of the Shingrix vaccine and its benefits in preventing a painful disease like shingles.
Time.news Editor: thank you, Dr. Roux, for sharing your insights. Any final thoughts you’d like to leave with our readers?
Dr. Marie Claire Roux: I encourage seniors and immunocompromised individuals to take advantage of this opportunity provided by the French health authorities. The Shingrix vaccine is an excellent way to protect against shingles, and now that it’s partially reimbursed, there is no better time to consider getting vaccinated. Let’s work together to prioritize health and well-being!
Time.news Editor: Thank you once again for your valuable insights, Dr. Roux. We appreciate your time and expertise on this crucial topic.